Favorable impact of the t(9;11) in childhood acute myeloid leukemia

被引:114
作者
Rubnitz, JE
Raimondi, SC
Tong, X
Srivastava, DK
Razzouk, B
Shurtleff, SA
Downing, JR
Pui, CH
Ribeiro, RC
Behm, FG
机构
[1] St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA
[2] St Jude Childrens Res Hosp, Dept Biostat, Memphis, TN 38105 USA
[3] St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA
[4] Univ Tennessee, Coll Med, Dept Pediat, Memphis, TN USA
关键词
D O I
10.1200/JCO.2002.08.400
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose : To determine the impact of MLL rearrangements on the outcome of children with acute myeloid leukemic (AML). Patients and Methods: We analyzed the clinical and biologic features of 298 infants and children with primary AML treated on four consecutive institutional clinical trials. The Kaplan-Meier method was used in survival analysis and the Cox proportional-hazards model was used to analyze the effect of potential prognostic factors on event-free survival (+/- 1 SE). Results: Molecular studies of 152 cases detected 42 with MILL rearrangements. The karyotypes of these 42 revealed the t(9;1 1) (15 cases), abnormalities of chromosomes 10 and I I (nine cases), the t(l 1, 19) (four cases), other abnormalities of 11 q23 (seven cases), and miscellaneous rearrangements (seven cases). Among these 42 patients, the 15 whose leukemic cells carried the t(9;1 1) had a better outcome (66% +/- 15%) than the other 27 (25.9% +/- 11.2%; P =.004). Cases with the t(9;11) were also characterized by M5 AML morphology (21 of 23 cases). Of the 63 patients with M5 AML, the 21 whose leukemic cells demonstrated the t(9;1 1) had a better outcome (71.1 % +/- 11%) than the other 42 (25.8% +/- 7.9%, P =.0004). The only independent factors indicating a favorable prognosis were presenting leukocyte count less than 50 x 10(9)/L (relative risk of relapse, 0.73, 95% confidence interval, 0.55 to 0.97; P =.03) and the t(9;1 1) (relative risk of relapse, 0.32; 95% confidence interval, 0.16 to 0.64, P =.002). Conclusion: We conclude that the t(9;1 1) is the most favorable genetic factor for patients with AML treated at our institution. (C) 2002 by American Society of Clinical Oncology.
引用
收藏
页码:2302 / 2309
页数:8
相关论文
共 33 条
[1]   Treatment of childhood acute myelogenous leukemia with an intensive regimen (AML-87) that individualizes etoposide and cytarabine dosages: short- and long-term effects [J].
Arnaout, MK ;
Radomski, KM ;
Srivastava, DK ;
Tong, X ;
Belt, JR ;
Raimondi, SC ;
Behm, FG ;
Santana, VM ;
Crom, WR ;
Mirro, J ;
Ribeiro, RC .
LEUKEMIA, 2000, 14 (10) :1736-1742
[2]   Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience [J].
Athale, UH ;
Razzouk, BI ;
Raimondi, SC ;
Tong, X ;
Behm, FG ;
Head, DR ;
Srivastava, DK ;
Rubnitz, JE ;
Bowman, L ;
Pui, CH ;
Ribeiro, RC .
BLOOD, 2001, 97 (12) :3727-3732
[3]   Rearrangement of the MLL gene confers a poor prognosis in childhood acute lymphoblastic leukemia, regardless of presenting age [J].
Behm, FG ;
Raimondi, SC ;
Frestedt, JL ;
Liu, Q ;
Crist, WM ;
Downing, JR ;
Rivera, GK ;
Kersey, JH ;
Pui, CH .
BLOOD, 1996, 87 (07) :2870-2877
[4]  
Bloomfield CD, 1998, CANCER RES, V58, P4173
[5]   Molecular analysis of the CALM/AF10 fusion: identical rearrangements in acute myeloid leukemia, acute lymphoblastic leukemia and malignant lymphoma patients [J].
Bohlander, SK ;
Muschinsky, V ;
Schrader, K ;
Siebert, R ;
Schlegelberger, B ;
Harder, L ;
Schemmel, V ;
Fonatsch, C ;
Ludwig, WD ;
Hiddemann, W ;
Dreyling, MH .
LEUKEMIA, 2000, 14 (01) :93-99
[6]   Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered [J].
Byrd, JC ;
Dodge, RK ;
Carroll, A ;
Baer, MR ;
Edwards, C ;
Stamberg, J ;
Qumsiyeh, M ;
Moore, JO ;
Mayer, RJ ;
Davey, F ;
Schiffer, CA ;
Bloomfield, CD .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (12) :3767-3775
[7]   Identification and molecular characterization of CALM/AF10 fusion products in T cell acute lymphoblastic leukemia and acute myeloid leukemia [J].
Carlson, KM ;
Vignon, C ;
Bohlander, S ;
Martinez-Climent, JA ;
Le Beau, MM ;
Rowley, JD .
LEUKEMIA, 2000, 14 (01) :100-104
[8]   Prognostic factors in children and adolescents with acute myeloid leukemia (excluding children with Down syndrome and acute promyelocytic leukemia): univariate and recursive partitioning analysis of patients treated on Pediatric Oncology Group (POC) Study 8821 [J].
Chang, M ;
Raimondi, SC ;
Ravindranath, Y ;
Carroll, AJ ;
Camitta, B ;
Gresik, MV ;
Steuber, CP ;
Weinstein, H .
LEUKEMIA, 2000, 14 (07) :1201-1207
[9]   THE T(10-11) TRANSLOCATION IN ACUTE MYELOID-LEUKEMIA (M5) CONSISTENTLY FUSES THE LEUCINE-ZIPPER MOTIF OF AF10 ONTO THE HRX GENE [J].
CHAPLIN, T ;
BERNARD, O ;
BEVERLOO, HB ;
SAHA, V ;
HAGEMEIJER, A ;
BERGER, R ;
YOUNG, BD .
BLOOD, 1995, 86 (06) :2073-2076
[10]   A NOVEL CLASS OF ZINC-FINGER LEUCINE-ZIPPER GENES IDENTIFIED FROM THE MOLECULAR-CLONING OF THE T(10-11) TRANSLOCATION IN ACUTE-LEUKEMIA [J].
CHAPLIN, T ;
AYTON, P ;
BERNARD, OA ;
SAHA, V ;
DELLAVALLE, V ;
HILLION, J ;
GREGORINI, A ;
LILLINGTON, D ;
BERGER, R ;
YOUNG, BD .
BLOOD, 1995, 85 (06) :1435-1441